TD Cowen analyst Brendan Smith initiated coverage of Arrowhead with an Outperform rating. The company’s liver-targeted RNAi offers potentially best-in-class efficacy across multiple sizable markets, the analyst tells investors in a research note. The firm says the upcoming Phase 2/3 data should solidify confidence in Arrowhead’s cardiometabolic portfolio and support first approval by 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARWR:
- Arrowhead files application for clearance to initiate ARO-DUX4 trial
- Arrowhead management to meet with B. Riley
- B. Riley biotechnology analysts to hold an analyst/industry conference call
- Arrowhead files for regulatory clearance to initiate a Phase 1 study of ARO-SOD1
- Arrowhead presents updated data from Phase 2 SEQUOIA study
